Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

Company Overview

Adial Pharmaceuticals, Inc., incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence. This extended-release formulation aims to improve compliance and reduce relapse rates by maintaining therapeutic drug levels without the need for daily dosing. In addition to AD04, Adial is evaluating next-generation implant platforms and potential adjunctive therapies for substance use disorders, seeking to broaden its pipeline through strategic collaborations and in-house research efforts.

Adial conducts clinical research primarily in North America, with previous trials extending to select international sites to gather comprehensive safety and efficacy data supporting future regulatory filings. The company operates through partnerships with academic institutions, contract research organizations and specialized clinical investigators to advance its development programs. Led by an executive team with extensive experience in pharmaceutical development, regulatory affairs and commercialization, Adial Pharmaceuticals continues to focus on addressing global challenges in addiction medicine and preparing for regulatory submissions that could pave the way for market entry.

Key Stats

• Today's Range: $3.70 to $4.87
• 50-Day Range: $2.13 to $4.80
• 52-Week Range: $1.31 to $10.75
• Volume: 100,610 shs
• Average Volume: 60,380 shs
• Market Capitalization: $8.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.63
• Consensus Rating: Hold

Adial Pharmaceuticals Stock Analysis - MarketRank™

Adial Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 360th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Adial Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Adial Pharmaceuticals has a consensus price target of $15.63, representing about 292.6% upside from its current price of $3.98.

Amount of Analyst Coverage

Adial Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Adial Pharmaceuticals is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adial Pharmaceuticals is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adial Pharmaceuticals has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.58% of the float of Adial Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Adial Pharmaceuticals has a short interest ratio ("days to cover") of 5.34.

Change versus previous month

Short interest in Adial Pharmaceuticals has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adial Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Adial Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.33

News Sentiment

Adial Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Adial Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

2 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $97,638.00 in company stock, which represents 1.1442% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Adial Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $97,638.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.86% of the stock of Adial Pharmaceuticals is held by insiders.

Percentage Held by Institutions

16.41% of the stock of Adial Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 8/09/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ADIL
• CIK: 1513525
• Web: www.adialpharma.com
• Phone: (434) 422-9800
• Fax: N/A
• Employees: 20
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Adial Pharmaceuticals: $15.63
• High Price Target: $37.50
• Low Price Target: $6.00
• Potential Upside/Downside: +292.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -162.82%
• Return on Assets: -127.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.18
• Quick Ratio: 3.18

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.75 per share
• Price / Book: 0.84

Miscellaneous

• Outstanding Shares: 2,144,000
• Free Float: 2,104,000
• Market Cap: $8.53 million
• Optionable: No Data
• Beta: 1.39